When the alarm bells rang in the Democratic Republic of Congo and Uganda, signalling the return of Ebola, health workers on the ground felt a familiar chill. But this time, the enemy wearing the familiar mask of hemorrhagic fever had a different name: Bundibugyo.
For the doctors and nurses who suit up in heavy protective gear, this changes everything. When the notorious Zaire strain of Ebola strikes, they at least have a known playbook and a licensed vaccine. But Bundibugyo is a different beast entirely. Right now, there are zero approved treatments or vaccines specifically designed to stop it. The medical cabinet is essentially empty for this specific threat.
Faced with a virus that causes the same devastating symptoms relentless fever, agonizing muscle pain, severe vomiting, and terrifying unexplained bleeding the World Health Organization had to make a difficult call. They brought together their heaviest hitters: virologists, immunologists, and epidemic response experts. The question on the table wasn't just how to fight this virus, but how to fight it responsibly.
The temptation in the middle of a terrifying outbreak is to throw every experimental drug you have at the problem. But the WHO experts drew a hard line. They told the world that promising new treatments and vaccines must be strictly locked behind the doors of properly designed clinical trials. It sounds bureaucratic, but it is deeply human. Giving an untested drug to a terrified patient and hoping for the best isn't medicine; it's gambling. If something goes wrong, or if it turns out the drug doesn't work, you lose the patient, and you lose the public's trust. In outbreak zones, trust is the most fragile and valuable currency you have.
So, what exactly is going into those trials? For patients already fighting for their lives in isolation wards, the WHO has flagged a few lifelines to test. The first are monoclonal antibodies, specifically drugs called MBP134 and Maftivimab. Think of these as precision-guided missiles. They are created in a lab to look exactly like the antibodies your body would naturally make, but they are engineered to latch onto the Bundibugyo virus and neutralize it, giving the patient's exhausted immune system a much-needed boost.
Alongside those, doctors will be testing remdesivir, an antiviral drug that essentially acts as a wrench thrown into the virus's machinery, stopping it from copying itself inside human cells. Researchers are even toying with the idea of hitting the virus from both sides at once, giving a patient a monoclonal antibody to neutralize the existing virus while using remdesivir to stop it from multiplying.
But you don't just want to treat the sick; you want to stop people from getting sick in the first place. This is where post-exposure prophylaxis, or PEP, comes in. Imagine you are a family member who just cared for a sick loved one, or a healthcare worker who suffered a needle-stick injury. You aren't sick yet, but the virus might be inside you. The experts want to test an oral antiviral pill called obeldesivir on these contacts to see if it can kill the virus before it ever takes hold. Of course, there is a massive catch: you can only give a pill to a contact if you can actually find them. In the dense, sometimes inaccessible regions of the DRC, contact tracing is a gruelling, muddy, shoe-leather operation that doesn't always go perfectly.
Then there is the holy grail of outbreak response: a vaccine. Two candidate vaccines are currently racing toward the field. The first, rVSV Bundibugyo, is being developed by the International AIDS Vaccine Initiative. It’s designed to be a single shot, offering a quick shield. But the reality of vaccine production means it won't be ready for human trials for another seven to nine months. That is an eternity in outbreak time.
The second candidate, ChAdOx1 Bundibugyo, comes from a collaboration between Oxford University and the Serum Institute of India. This one could be ready to test in humans in just two to three months. Scientists are still waiting on the final results from animal trials before giving it the green light, but the hope is that it could be given as a single shot to people exposed to the virus, or as a two-dose series for healthcare workers who are constantly in the line of fire.
Naturally, people are asking: what about Ervebo? Ervebo is the only Ebola vaccine we actually have licensed and ready to go. It revolutionized the fight against the Zaire strain. But viruses are tricky, and different species within the Ebola family don't always behave the same way. The hard truth is that we simply do not know if Ervebo protects against Bundibugyo. The data just isn't there. The WHO has made it clear that using Ervebo outside of a carefully monitored research study during this outbreak would be a mistake. You can't assume a shield built for one sword will block a different one.
Behind all the scientific names and trial protocols are the people doing the work. The WHO isn't acting alone. They are standing shoulder-to-shoulder with the health ministries of Congo and Uganda, the Africa Centres for Disease Control and Prevention, and groups like the French ANRS. Together, they are drafting trial protocols that respect the humans who will participate in them. That means making sure a scared patient truly understands what they are signing up for, that their rights are protected, and that the community feels like a partner in the science, not a testing ground.
While the world waits for these clinical trials to get off the ground, the brutal, unglamorous work of stopping an outbreak continues. Science takes months; the virus takes days. So, while researchers tweak formulas in labs, local health workers are out in the rain and the heat, tracking down every single person who touched a sick patient. They are setting up isolation wards, handing out protective gear, and sitting down with community leaders to fight the fear and stigma that always accompanies Ebola. They are ensuring that when people die, they are buried safely and with dignity, breaking the chain of transmission that so often spreads the virus at funerals.
The Bundibugyo outbreak is a stark reminder that we are still catching up to nature. The tools in our medical kit are impressive, but they are not universal. By insisting on rigorous, ethical clinical trials now, the global health community is choosing to build a foundation of solid science rather than take dangerous shortcuts. It is a harder path, but it is the only one that leads to real, lasting cures.
More on clinical trials: read here